RGEN
Repligen CorporationNASDAQHEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES
Key Statistics
Market Cap
$6.75B
P/E Ratio
139.27
EPS
$0.86
Beta
1.19
52W High
$175.77
52W Low
$109.66
50-Day MA
$129.93
200-Day MA
$138.23
Dividend Yield
—
Profit Margin
6.62%
Forward P/E
59.52
PEG Ratio
8.23
About Repligen Corporation
Repligen Corporation develops and markets bioprocessing systems and technologies for use in the biologic drug manufacturing process in North America, Europe, Asia Pacific, and internationally. The company is headquartered in Waltham, Massachusetts.
Fundamentals
| Revenue (TTM) | $738.26M |
| Gross Profit (TTM) | $388.71M |
| EBITDA | $124.44M |
| Operating Margin | 8.26% |
| Return on Equity | 2.40% |
| Return on Assets | 0.99% |
| Revenue/Share (TTM) | $13.13 |
| Book Value | $37.39 |
| Price-to-Book | 3.13 |
| Price-to-Sales (TTM) | 9.15 |
| EV/Revenue | 8.83 |
| EV/EBITDA | 36.04 |
| Quarterly Earnings Growth (YoY) | 160.00% |
| Quarterly Revenue Growth (YoY) | 18.10% |
| Shares Outstanding | $56.40M |
| Float | $53.25M |
| % Insiders | 5.38% |
| % Institutions | 112.72% |
Analyst Ratings
Consensus ($185.06 target)
3
Strong Buy13
Buy4
HoldData last updated: 4/9/2026